York Against Cancer Enthuse partnership - cBioPortal P53 practical: Case Study 2

York Against Cancer Enthuse partnership - cBioPortal P53 practical: Case Study 2

York Against Cancer Enthuse partnership - cBioPortal P53 practical: Case Study 3Подробнее

York Against Cancer Enthuse partnership - cBioPortal P53 practical: Case Study 3

York Against Cancer Enthuse partnership - cBioPortal P53 practical: Case Study 1Подробнее

York Against Cancer Enthuse partnership - cBioPortal P53 practical: Case Study 1

i-SAbR: Enhancing immunotherapy with stereotactic radiationПодробнее

i-SAbR: Enhancing immunotherapy with stereotactic radiation

simKAP: Simulation framework for the kidney allocation process: a shared decision-making modelПодробнее

simKAP: Simulation framework for the kidney allocation process: a shared decision-making model

Key objectives in kidney cancer: treatment sequencing & refining clinical endpointsПодробнее

Key objectives in kidney cancer: treatment sequencing & refining clinical endpoints

Strategies for managing gastric cancer in North AmericaПодробнее

Strategies for managing gastric cancer in North America

Novel Combinations in Kidney CancerПодробнее

Novel Combinations in Kidney Cancer

New Breakthroughs in Nuclear Medicine Help Prostate Cancer PatientsПодробнее

New Breakthroughs in Nuclear Medicine Help Prostate Cancer Patients

Summa Health & WOIO feature a Medical Minute with Lung Cancer expert, Dr. Kennedy-Snodgrass Oct 2022Подробнее

Summa Health & WOIO feature a Medical Minute with Lung Cancer expert, Dr. Kennedy-Snodgrass Oct 2022

Kidney Cancer Patients - 3250Подробнее

Kidney Cancer Patients - 3250

Dr. Sweis on Immunotherapy Combinations in Kidney CancerПодробнее

Dr. Sweis on Immunotherapy Combinations in Kidney Cancer

U.S. National Cancer Institute perspective on Precision OncologyПодробнее

U.S. National Cancer Institute perspective on Precision Oncology

Harmful crosstalk among tumor-associated cells leads to shorter survival after treatmentПодробнее

Harmful crosstalk among tumor-associated cells leads to shorter survival after treatment

Metastatic cSCC Diagnostic Work-Up and Risk AssessmentПодробнее

Metastatic cSCC Diagnostic Work-Up and Risk Assessment

Radiology Case Conference 8/17Подробнее

Radiology Case Conference 8/17

Case Study 3: CRPC resistant to AR-directed therapiesПодробнее

Case Study 3: CRPC resistant to AR-directed therapies

Cancer Immunotherapy Workshop 2021 – Q&A on Trial DesignПодробнее

Cancer Immunotherapy Workshop 2021 – Q&A on Trial Design

Актуальное